Opus Genetics Reports Retinal Gene Therapy Progress
Phase 1/2 data shows sustained vision gains for treated patients, with phase 3 trials expected to launch in late 2026.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should the government prioritize rapid approval for gene therapies targeting rare inherited retinal diseases?
Opus Genetics has released interim phase 1/2 clinical data for two experimental gene therapies, OPGx-LCA5 and OPGx-BEST1. The studies demonstrated sustained visual gains in patients with inherited retinal diseases, with phase 3 trials for OPGx-LCA5 expected to begin in 2026.
Why it matters
These results provide evidence for AAV-based gene delivery in treating Leber congenital amaurosis and related retinal conditions. The clinical progress indicates a potential shift toward disease-modifying interventions for inherited blindness.
Participants in the OPGx-LCA5 study received a dose of 1 × 10¹⁰ vector genomes per eye via subretinal administration. Treated adults maintained visual acuity improvements for 24 months, while pediatric subjects reached normal cone-mediated vision ranges within six months.
The players
Opus Genetics
A biotechnology firm focused on developing gene therapies for inherited retinal diseases through AAV-based delivery platforms.
The details
OPGx-LCA5 is an AAV8-based gene therapy, using an adeno-associated virus—a modified harmless virus used as a delivery vehicle—to introduce functional genetic material to the retina. It addresses Leber congenital amaurosis type 5, a condition where mutations disrupt lebercilin protein production. The therapy is delivered via a one-time subretinal injection to restore cellular function.
Timeline
Adults showed sustained visual acuity improvements through 2024.
Clinical data was presented at Retina in Rio in October 2026.
Dosing for the OPGx-LCA5 phase 3 trial is expected in Q4 2026.
The Tech Race
This research follows established efforts to address inherited blindness using AAV vectors to correct specific genetic mutations. Opus Genetics is currently aligning its data to meet the clinical endpoints required for upcoming phase 3 trials.
The therapy is currently in the experimental stage and requires clinical trial participation for access. Patients with LCA5 mutations should consult with specialists regarding future trial enrollment or site-specific availability.
The takeaway
These findings establish a 24-month horizon for sustained visual acuity improvement using AAV8 delivery. Interested parties should monitor the phase 3 trial commencement in late 2026 for the defined primary efficacy endpoint: retinal sensitivity across 16 test locations.
What happens next
Dosing for the OPGx-LCA5 phase 3 trial is scheduled to begin in the fourth quarter of 2026.
Further reading
For more on the current landscape of gene-based ocular treatments, visit our Biotech section.
Source note: This article includes information reported by BioPharm International.
Live Poll
Should the government prioritize rapid approval for gene therapies targeting rare inherited retinal diseases?
